SARS-CoV-2 Mutation Detail Information

Virus Mutation SARS-CoV-2 Mutation E484K


Basic Characteristics of Mutations
Mutation Site E484K
Mutation Site Sentence All have mutations in the ACE2 binding site; with P.1 and B.1.351 having a virtually identical triplet (E484K; K417N/T; and N501Y); which we show confer similar increased affinity for ACE2.
Mutation Level Amino acid level
Mutation Type Nonsynonymous substitution
Gene/Protein/Region S
Standardized Encoding Gene S  
Genotype/Subtype P.1
Viral Reference -
Functional Impact and Mechanisms
Disease COVID-19    
Immune -
Target Gene -
Clinical and Epidemiological Correlations
Clinical Information -
Treatment -
Location Brazil
Literature Information
PMID 33852911
Title Antibody evasion by the P.1 strain of SARS-CoV-2
Author Dejnirattisai W,Zhou D,Supasa P,Liu C,Mentzer AJ,Ginn HM,Zhao Y,Duyvesteyn HME,Tuekprakhon A,Nutalai R,Wang B,Lopez-Camacho C,Slon-Campos J,Walter TS,Skelly D,Costa Clemens SA,Naveca FG,Nascimento V,Nascimento F,Fernandes da Costa C,Resende PC,Pauvolid-Correa A,Siqueira MM,Dold C,Levin R,Dong T,Pollard AJ,Knight JC,Crook D,Lambe T,Clutterbuck E,Bibi S,Flaxman A,Bittaye M,Belij-Rammerstorfer S,Gilbert SC,Carroll MW,Klenerman P,Barnes E,Dunachie SJ,Paterson NG,Williams MA,Hall DR,Hulswit RJG,Bowden TA,Fry EE,Mongkolsapaya J,Ren J,Stuart DI,Screaton GR
Journal Cell
Journal Info 2021 May 27;184(11):2939-2954
Abstract Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates. However, new strains have emerged with multiple mutations, including P.1 from Brazil, B.1.351 from South Africa, and B.1.1.7 from the UK (12, 10, and 9 changes in the spike, respectively). All have mutations in the ACE2 binding site, with P.1 and B.1.351 having a virtually identical triplet (E484K, K417N/T, and N501Y), which we show confer similar increased affinity for ACE2. We show that, surprisingly, P.1 is significantly less resistant to naturally acquired or vaccine-induced antibody responses than B.1.351, suggesting that changes outside the receptor-binding domain (RBD) impact neutralization. Monoclonal antibody (mAb) 222 neutralizes all three variants despite interacting with two of the ACE2-binding site mutations. We explain this through structural analysis and use the 222 light chain to largely restore neutralization potency to a major class of public antibodies.
Sequence Data -
Mutation Information
Note
Basic Characteristics of Mutations
  • Mutation Site: The specific location in a gene or protein sequence where a change occurs.
  • Mutation Level: The level at which a mutation occurs, including the nucleotide or amino acid level.
  • Mutation Type: The nature of the mutation, such as missense mutation, nonsense mutation, synonymous mutation, etc.
  • Gene/Protein/Region: Refers to the specific region of the virus where the mutation occurs. Including viral genes, viral proteins, or a specific viral genome region. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main
  • Gene/Protein/Region studied in the article is marked.
  • Genotype/Subtype: Refers to the viral genotype or subtype where the mutation occurs. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main Genotype/Subtype studied in the article is marked.
  • Viral Reference: Refers to the standard virus strain used to compare and analyze viral sequences.
Functional Impact and Mechanisms
  • Disease: An abnormal physiological state with specific symptoms and signs caused by viral infection.
  • Immune: The article focuses on the study of mutations and immune.
  • Target Gene: Host genes that viral mutations may affect.
Clinical and Epidemiological Correlations
  • Clinical Information: The study is a clinical or epidemiological study and provides basic information about the population.
  • Treatment: The study mentioned a certain treatment method, such as drug resistance caused by mutations. If the study does not specifically indicate the relationship between mutations and their correspondence treatment, the main treatment studied in the article is marked.
  • Location: The source of the research data.
Literature Information
  • Sequence Data: The study provides the data accession number.